Pancreatic Cancer Research

ResearcherBaylor Research InstituteActive in the last 2 years

Ajay Goel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1396-6341; OpenAlex author ID A5101530683; NIH RePORTER profile ID 8552045. Sources: ClinicalTrials.gov.

Their work

Papers
34 (first author 2, last author 22)
Trials
4 (principal investigator on 4)
Grants
3
Labs led
3
Collaborators
99
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 4 papers · 2021: 5 papers · 2022: 6 papers · 2023: 3 papers, 1 trial · 2024: 3 papers, 3 trials · 2025: 2 papers · 2026: 6 papers, 3 grants

Papers 34

  1. An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer. Last author DOI 10.1001/jamasurg.2026.3840↗
  2. Cell-Selective Delivery of RIBOTACs via an Anti-EGFR Nanobody for Pancreatic Cancer Treatment. Co-author DOI 10.1002/advs.76575↗
  3. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41591-026-04625-x↗
  4. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Last author DOI 10.1038/s41591-026-04775-y↗
  5. METTL1-mediated m7G modification of valine tRNAs drives metabolic adaptation in pancreatic ductal adenocarcinoma cells. Last author DOI 10.1172/jci204312↗
  6. Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future. First author DOI 10.3322/caac.70035↗
  7. Informatics strategies for early detection and risk mitigation in pancreatic cancer patients. Co-author DOI 10.1016/j.neo.2025.101129↗
  8. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03167-2↗
  9. The LAMB3-EGFR signaling pathway mediates synergistic Anti-Cancer effects of berberine and emodin in Pancreatic cancer. Last author DOI 10.1016/j.bcp.2024.116509↗
  10. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2023.09.050↗
  11. Aronia Berry Extract Modulates MYD88/NF-kB/P-Glycoprotein Axis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Last author DOI 10.3390/ph17070911↗
  12. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41416-022-02057-1↗
  13. Intratumoral Malasseziaglobosa Levels Predict Survival and Therapeutic Response to Adjuvant Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2023.04.017↗
  14. Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/biomedicines11010119↗
  15. Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.apsb.2022.01.018↗
  16. Corrigendum to "Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma" [Semin. Cancer Biol. 75 (2021) 153-168]. Last author DOI 10.1016/j.semcancer.2022.01.002↗
  17. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Last author DOI 10.1053/j.gastro.2022.06.090↗
  18. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/sla.0000000000003945↗
  19. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Last author DOI 10.1097/sla.0000000000004993↗
  20. Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ph15101199↗
  21. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.33284↗
  22. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejca.2020.12.031↗
  23. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.semcancer.2020.10.001↗
  24. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinom… Last author DOI 10.1093/carcin/bgab011↗
  25. Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.678617↗
  26. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. Last author DOI 10.1053/j.gastro.2020.04.057↗
  27. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-19-4044↗
  28. Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Ea… Co-author DOI 10.3389/fonc.2020.596931↗
  29. Extracellular Vesicles in Diagnosis and Treatment of Pancreatic Cancer: Current State and Future Perspectives. Last author DOI 10.3390/cancers12061530↗
  30. Single molecule characterization of individual extracellular vesicles from pancreatic cancer. Co-author DOI 10.1080/20013078.2019.1685634↗
  31. Features of Immune Cells and the Tumor-Associated Stroma Tango as Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2018.10.008↗
  32. Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabiliz… Co-author DOI 10.1093/carcin/bgy114↗
  33. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. Last author DOI 10.1093/carcin/bgx065↗
  34. Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0042933↗

Trials 4

  1. A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer Principal investigator NCT07224750↗
  2. Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting Principal investigator NCT07224802↗
  3. Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer Principal investigator NCT07226154↗
  4. Pancreatic Cancer Detection Consortium Principal investigator NCT06388967↗

Grants 3

  1. A Blood-Based Test to Predict Pancreatic Cyst Progression AWARD stephenson:2026-ajay-goel-a-blood-based-test-to-predict-pancreatic
  2. Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer U01CA214254↗
  3. 5mC and 5hmC DNA alterations as sensitive and specific biomarkers for the non-invasive early detection of pancreatic ductal adenocarcinoma U01CA296639↗

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel D. Von Hoff · 14 shared papers, 1 shared grant, 2020–2026 · strength 3.65
  2. Haiyong Han · 8 shared papers, 2017–2026 · strength 1.41
  3. Caiming Xu · 6 shared papers, 2022–2026 · strength 1.38
  4. Song Cheol Kim · 6 shared papers, 2022–2026 · strength 1.12
  5. Mitsuro Kanda · 5 shared papers, 2023–2026 · strength 1.05
  6. Alessandro Mannucci · 3 shared papers, 2026 · strength 1.02
  7. Erkut Hasan Borazanci · 6 shared papers, 2021–2026 · strength 1.02
  8. Derek Cridebring · 6 shared papers, 2020–2026 · strength 0.98
  9. Cristina Fillat · 4 shared papers, 2022–2024 · strength 0.92
  10. Silvia Pascual-Sabater · 4 shared papers, 2022–2024 · strength 0.92
  11. Eunsung Jun · 5 shared papers, 2022–2026 · strength 0.82
  12. Satoshi Nishiwada · 6 shared papers, 2020–2023 · strength 0.78
  13. Vincent M. Chung · 4 shared papers, 2021–2026 · strength 0.76
  14. Yasuyuki Okada · 4 shared papers, 2021–2022 · strength 0.75
  15. Yasuhiro Kodera · 5 shared papers, 2022–2023 · strength 0.72
  16. John S. Bolton · 4 shared papers, 2022–2026 · strength 0.70
  17. Kensuke Yamamura · 5 shared papers, 2020–2023 · strength 0.68
  18. Masayuki Sho · 5 shared papers, 2020–2023 · strength 0.67
  19. Kota Nakamura · 5 shared papers, 2020–2023 · strength 0.63
  20. Keisuke Okuno · 3 shared papers, 2022–2023 · strength 0.53
  21. Tetsuji Takayama · 3 shared papers, 2021–2023 · strength 0.52
  22. Geeta G. Sharma · 3 shared papers, 2021–2022 · strength 0.52
  23. Joon Oh Park · 3 shared papers, 2022–2026 · strength 0.52
  24. Carlos Roberto Becerra · 3 shared papers, 2022–2026 · strength 0.50
  25. Susan Tsai · 3 shared papers, 2022–2025 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.